Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease

Identifieur interne : 000E88 ( Main/Corpus ); précédent : 000E87; suivant : 000E89

Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease

Auteurs : Joseph H. Friedman ; Guido Alves ; Peter Hagell ; Johan Marinus ; Laura Marsh ; Pablo Martinez-Martin ; Christopher G. Goetz ; Werner Poewe ; Olivier Rascol ; Cristina Sampaio ; Glenn Stebbins ; Anette Schrag

Source :

RBID : ISTEX:076625E4756FDC12B6C3DF53275FFFA0F813F43F

English descriptors

Abstract

Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was “recommended” if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of “recommended” differs from the use of this term in previous MDS task force scale reviews. “Suggested” scales failed to meet all the criteria of a “recommended” scale, usually the criterion of sensitivity to change in a study of PD. Scales were “listed” if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was “recommended” for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is “suggested” for both screening and severity. The Functional Assessment of Chronic Illness Therapy‐Fatigue was “recommended” for screening and “suggested” for severity. The Multidimensional Fatigue Inventory was “suggested” for screening and “recommended” for severity. The Parkinson Fatigue Scale was “recommended” for screening and “suggested” for severity rating. The Fatigue Severity Inventory was “listed” for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was “listed” for screening and “suggested” for severity. Visual Analogue and Global Impression Scales are both “listed” for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. © 2010 Movement Disorder Society

Url:
DOI: 10.1002/mds.22989

Links to Exploration step

ISTEX:076625E4756FDC12B6C3DF53275FFFA0F813F43F

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
<author>
<name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation>
<mods:affiliation>NeuroHealth, Parkinson's Disease and Movement Disorders Center, Warwick, Rhode Island, USA</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Neurology, Warren Alpert Medical School, Brown University, Rhode Island, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name>
<affiliation>
<mods:affiliation>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Neurology, Stavanger University Hospital, Stavanger, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name>
<affiliation>
<mods:affiliation>Department of Neurology, Lund University Hospital, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name>
<affiliation>
<mods:affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation>
<mods:affiliation>Department of Psychiatry Johns Hopkins Hospital, Baltimore, Maryland, USA</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation>
<mods:affiliation>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation>
<mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation>
<mods:affiliation>Clinical Investigation Center INSERM CIC‐9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation>
<mods:affiliation>Laboratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation>
<mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation>
<mods:affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, United Kingdom</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:076625E4756FDC12B6C3DF53275FFFA0F813F43F</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22989</idno>
<idno type="url">https://api.istex.fr/document/076625E4756FDC12B6C3DF53275FFFA0F813F43F/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000E88</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
<author>
<name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation>
<mods:affiliation>NeuroHealth, Parkinson's Disease and Movement Disorders Center, Warwick, Rhode Island, USA</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Neurology, Warren Alpert Medical School, Brown University, Rhode Island, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name>
<affiliation>
<mods:affiliation>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Neurology, Stavanger University Hospital, Stavanger, Norway</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name>
<affiliation>
<mods:affiliation>Department of Neurology, Lund University Hospital, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name>
<affiliation>
<mods:affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation>
<mods:affiliation>Department of Psychiatry Johns Hopkins Hospital, Baltimore, Maryland, USA</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation>
<mods:affiliation>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation>
<mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation>
<mods:affiliation>Clinical Investigation Center INSERM CIC‐9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation>
<mods:affiliation>Laboratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation>
<mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation>
<mods:affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, United Kingdom</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-05-15">2010-05-15</date>
<biblScope unit="volume">25</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="805">805</biblScope>
<biblScope unit="page" to="822">822</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">076625E4756FDC12B6C3DF53275FFFA0F813F43F</idno>
<idno type="DOI">10.1002/mds.22989</idno>
<idno type="ArticleID">MDS22989</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Parkinson's disease</term>
<term>fatigue</term>
<term>fatigue rating scales</term>
<term>rating scales</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was “recommended” if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of “recommended” differs from the use of this term in previous MDS task force scale reviews. “Suggested” scales failed to meet all the criteria of a “recommended” scale, usually the criterion of sensitivity to change in a study of PD. Scales were “listed” if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was “recommended” for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is “suggested” for both screening and severity. The Functional Assessment of Chronic Illness Therapy‐Fatigue was “recommended” for screening and “suggested” for severity. The Multidimensional Fatigue Inventory was “suggested” for screening and “recommended” for severity. The Parkinson Fatigue Scale was “recommended” for screening and “suggested” for severity rating. The Fatigue Severity Inventory was “listed” for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was “listed” for screening and “suggested” for severity. Visual Analogue and Global Impression Scales are both “listed” for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<author>
<json:item>
<name>Joseph H. Friedman MD</name>
<affiliations>
<json:string>NeuroHealth, Parkinson's Disease and Movement Disorders Center, Warwick, Rhode Island, USA</json:string>
<json:string>Department of Neurology, Warren Alpert Medical School, Brown University, Rhode Island, USA</json:string>
</affiliations>
</json:item>
<json:item>
<name>Guido Alves MD, PhD</name>
<affiliations>
<json:string>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</json:string>
<json:string>Department of Neurology, Stavanger University Hospital, Stavanger, Norway</json:string>
</affiliations>
</json:item>
<json:item>
<name>Peter Hagell RN, PhD</name>
<affiliations>
<json:string>Department of Neurology, Lund University Hospital, Lund, Sweden</json:string>
</affiliations>
</json:item>
<json:item>
<name>Johan Marinus PhD</name>
<affiliations>
<json:string>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>Laura Marsh MD</name>
<affiliations>
<json:string>Department of Psychiatry Johns Hopkins Hospital, Baltimore, Maryland, USA</json:string>
<json:string>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA</json:string>
<json:string>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA</json:string>
</affiliations>
</json:item>
<json:item>
<name>Pablo Martinez‐Martin MD, PhD</name>
<affiliations>
<json:string>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</json:string>
</affiliations>
</json:item>
<json:item>
<name>Christopher G. Goetz MD</name>
<affiliations>
<json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string>
</affiliations>
</json:item>
<json:item>
<name>Werner Poewe MD</name>
<affiliations>
<json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string>
</affiliations>
</json:item>
<json:item>
<name>Olivier Rascol MD</name>
<affiliations>
<json:string>Clinical Investigation Center INSERM CIC‐9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</json:string>
</affiliations>
</json:item>
<json:item>
<name>Cristina Sampaio MD, PhD</name>
<affiliations>
<json:string>Laboratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</json:string>
</affiliations>
</json:item>
<json:item>
<name>Glenn Stebbins MD</name>
<affiliations>
<json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string>
</affiliations>
</json:item>
<json:item>
<name>Anette Schrag MD, PhD</name>
<affiliations>
<json:string>Department of Clinical Neurosciences, Institute of Neurology, University College London, United Kingdom</json:string>
</affiliations>
</json:item>
</author>
<subject>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>fatigue</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Parkinson's disease</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>rating scales</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>fatigue rating scales</value>
</json:item>
</subject>
<articleId>
<json:string>MDS22989</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<abstract>Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was “recommended” if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of “recommended” differs from the use of this term in previous MDS task force scale reviews. “Suggested” scales failed to meet all the criteria of a “recommended” scale, usually the criterion of sensitivity to change in a study of PD. Scales were “listed” if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was “recommended” for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is “suggested” for both screening and severity. The Functional Assessment of Chronic Illness Therapy‐Fatigue was “recommended” for screening and “suggested” for severity. The Multidimensional Fatigue Inventory was “suggested” for screening and “recommended” for severity. The Parkinson Fatigue Scale was “recommended” for screening and “suggested” for severity rating. The Fatigue Severity Inventory was “listed” for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was “listed” for screening and “suggested” for severity. Visual Analogue and Global Impression Scales are both “listed” for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. © 2010 Movement Disorder Society</abstract>
<qualityIndicators>
<score>8</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>612 x 810 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<keywordCount>4</keywordCount>
<abstractCharCount>2804</abstractCharCount>
<pdfWordCount>12680</pdfWordCount>
<pdfCharCount>81420</pdfCharCount>
<pdfPageCount>18</pdfPageCount>
<abstractWordCount>435</abstractWordCount>
</qualityIndicators>
<title>Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
<genre>
<json:string>review-article</json:string>
</genre>
<host>
<volume>25</volume>
<publisherId>
<json:string>MDS</json:string>
</publisherId>
<pages>
<total>18</total>
<last>822</last>
<first>805</first>
</pages>
<issn>
<json:string>0885-3185</json:string>
</issn>
<issue>7</issue>
<subject>
<json:item>
<value>Review</value>
</json:item>
</subject>
<genre>
<json:string>Journal</json:string>
</genre>
<language>
<json:string>unknown</json:string>
</language>
<eissn>
<json:string>1531-8257</json:string>
</eissn>
<title>Movement Disorders</title>
<doi>
<json:string>10.1002/(ISSN)1531-8257</json:string>
</doi>
</host>
<publicationDate>2010</publicationDate>
<copyrightDate>2010</copyrightDate>
<doi>
<json:string>10.1002/mds.22989</json:string>
</doi>
<id>076625E4756FDC12B6C3DF53275FFFA0F813F43F</id>
<fulltext>
<json:item>
<original>true</original>
<mimetype>application/pdf</mimetype>
<extension>pdf</extension>
<uri>https://api.istex.fr/document/076625E4756FDC12B6C3DF53275FFFA0F813F43F/fulltext/pdf</uri>
</json:item>
<json:item>
<original>false</original>
<mimetype>application/zip</mimetype>
<extension>zip</extension>
<uri>https://api.istex.fr/document/076625E4756FDC12B6C3DF53275FFFA0F813F43F/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/076625E4756FDC12B6C3DF53275FFFA0F813F43F/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main" xml:lang="en">Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability>
<p>WILEY</p>
</availability>
<date>2010</date>
</publicationStmt>
<notesStmt>
<note type="content">*Potential conflict of interest: None.</note>
</notesStmt>
<sourceDesc>
<biblStruct type="inbook">
<analytic>
<title level="a" type="main" xml:lang="en">Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
<author>
<persName>
<forename type="first">Joseph H.</forename>
<surname>Friedman</surname>
</persName>
<roleName type="degree">MD</roleName>
<note type="correspondence">
<p>Correspondence: NeuroHealth, 227 Centerville Rd, Warwick, RI 02886</p>
</note>
<affiliation>NeuroHealth, Parkinson's Disease and Movement Disorders Center, Warwick, Rhode Island, USA</affiliation>
<affiliation>Department of Neurology, Warren Alpert Medical School, Brown University, Rhode Island, USA</affiliation>
</author>
<author>
<persName>
<forename type="first">Guido</forename>
<surname>Alves</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</affiliation>
<affiliation>Department of Neurology, Stavanger University Hospital, Stavanger, Norway</affiliation>
</author>
<author>
<persName>
<forename type="first">Peter</forename>
<surname>Hagell</surname>
</persName>
<roleName type="degree">RN, PhD</roleName>
<affiliation>Department of Neurology, Lund University Hospital, Lund, Sweden</affiliation>
</author>
<author>
<persName>
<forename type="first">Johan</forename>
<surname>Marinus</surname>
</persName>
<roleName type="degree">PhD</roleName>
<affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</affiliation>
</author>
<author>
<persName>
<forename type="first">Laura</forename>
<surname>Marsh</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Department of Psychiatry Johns Hopkins Hospital, Baltimore, Maryland, USA</affiliation>
<affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA</affiliation>
<affiliation>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA</affiliation>
</author>
<author>
<persName>
<forename type="first">Pablo</forename>
<surname>Martinez‐Martin</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation>
</author>
<author>
<persName>
<forename type="first">Christopher G.</forename>
<surname>Goetz</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation>
</author>
<author>
<persName>
<forename type="first">Werner</forename>
<surname>Poewe</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation>
</author>
<author>
<persName>
<forename type="first">Olivier</forename>
<surname>Rascol</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Clinical Investigation Center INSERM CIC‐9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</affiliation>
</author>
<author>
<persName>
<forename type="first">Cristina</forename>
<surname>Sampaio</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>Laboratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</affiliation>
</author>
<author>
<persName>
<forename type="first">Glenn</forename>
<surname>Stebbins</surname>
</persName>
<roleName type="degree">MD</roleName>
<affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation>
</author>
<author>
<persName>
<forename type="first">Anette</forename>
<surname>Schrag</surname>
</persName>
<roleName type="degree">MD, PhD</roleName>
<affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, United Kingdom</affiliation>
</author>
</analytic>
<monogr>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="pISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<idno type="DOI">10.1002/(ISSN)1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-05-15"></date>
<biblScope unit="volume">25</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="805">805</biblScope>
<biblScope unit="page" to="822">822</biblScope>
</imprint>
</monogr>
<idno type="istex">076625E4756FDC12B6C3DF53275FFFA0F813F43F</idno>
<idno type="DOI">10.1002/mds.22989</idno>
<idno type="ArticleID">MDS22989</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<creation>
<date>2010</date>
</creation>
<langUsage>
<language ident="en">en</language>
</langUsage>
<abstract xml:lang="en">
<p>Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was “recommended” if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of “recommended” differs from the use of this term in previous MDS task force scale reviews. “Suggested” scales failed to meet all the criteria of a “recommended” scale, usually the criterion of sensitivity to change in a study of PD. Scales were “listed” if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was “recommended” for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is “suggested” for both screening and severity. The Functional Assessment of Chronic Illness Therapy‐Fatigue was “recommended” for screening and “suggested” for severity. The Multidimensional Fatigue Inventory was “suggested” for screening and “recommended” for severity. The Parkinson Fatigue Scale was “recommended” for screening and “suggested” for severity rating. The Fatigue Severity Inventory was “listed” for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was “listed” for screening and “suggested” for severity. Visual Analogue and Global Impression Scales are both “listed” for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. © 2010 Movement Disorder Society</p>
</abstract>
<textClass xml:lang="en">
<keywords scheme="keyword">
<list>
<head>Keywords</head>
<item>
<term>fatigue</term>
</item>
<item>
<term>Parkinson's disease</term>
</item>
<item>
<term>rating scales</term>
</item>
<item>
<term>fatigue rating scales</term>
</item>
</list>
</keywords>
</textClass>
<textClass>
<keywords scheme="Journal Subject">
<list>
<head>article category</head>
<item>
<term>Review</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc>
<change when="2009-07-20">Received</change>
<change when="2009-12-11">Registration</change>
<change when="2010-05-15">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<original>false</original>
<mimetype>text/plain</mimetype>
<extension>txt</extension>
<uri>https://api.istex.fr/document/076625E4756FDC12B6C3DF53275FFFA0F813F43F/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley, elements deleted: body">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1531-8257</doi>
<issn type="print">0885-3185</issn>
<issn type="electronic">1531-8257</issn>
<idGroup>
<id type="product" value="MDS"></id>
</idGroup>
<titleGroup>
<title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title>
<title type="short">Mov. Disord.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="70">
<doi origin="wiley" registered="yes">10.1002/mds.v25:7</doi>
<numberingGroup>
<numbering type="journalVolume" number="25">25</numbering>
<numbering type="journalIssue">7</numbering>
</numberingGroup>
<coverDate startDate="2010-05-15">15 May 2010</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="reviewArticle" position="10" status="forIssue">
<doi origin="wiley" registered="yes">10.1002/mds.22989</doi>
<idGroup>
<id type="unit" value="MDS22989"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="18"></count>
</countGroup>
<titleGroup>
<title type="articleCategory">Review</title>
<title type="tocHeading1">Reviews</title>
</titleGroup>
<copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright>
<eventGroup>
<event type="manuscriptReceived" date="2009-07-20"></event>
<event type="manuscriptRevised" date="2009-11-09"></event>
<event type="manuscriptAccepted" date="2009-12-11"></event>
<event type="firstOnline" date="2010-04-13"></event>
<event type="publishedOnlineFinalForm" date="2010-05-05"></event>
<event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-04-13"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-08-12"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst">805</numbering>
<numbering type="pageLast">822</numbering>
</numberingGroup>
<correspondenceTo>NeuroHealth, 227 Centerville Rd, Warwick, RI 02886</correspondenceTo>
<linkGroup>
<link type="toTypesetVersion" href="file:MDS.MDS22989.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<countGroup>
<count type="figureTotal" number="0"></count>
<count type="tableTotal" number="1"></count>
<count type="referenceTotal" number="142"></count>
<count type="wordTotal" number="13773"></count>
</countGroup>
<titleGroup>
<title type="main" xml:lang="en">Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease
<link href="#fn1"></link>
</title>
<title type="short" xml:lang="en">Fatigue Rating Scales for Parkinson's Disease</title>
</titleGroup>
<creators>
<creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes">
<personName>
<givenNames>Joseph H.</givenNames>
<familyName>Friedman</familyName>
<degrees>MD</degrees>
</personName>
<contactDetails>
<email>joseph_friedman@brown.edu</email>
</contactDetails>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af3 #af4">
<personName>
<givenNames>Guido</givenNames>
<familyName>Alves</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af5">
<personName>
<givenNames>Peter</givenNames>
<familyName>Hagell</familyName>
<degrees>RN, PhD</degrees>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af6">
<personName>
<givenNames>Johan</givenNames>
<familyName>Marinus</familyName>
<degrees>PhD</degrees>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af7 #af8 #af9">
<personName>
<givenNames>Laura</givenNames>
<familyName>Marsh</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af10">
<personName>
<givenNames>Pablo</givenNames>
<familyName>Martinez‐Martin</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af11">
<personName>
<givenNames>Christopher G.</givenNames>
<familyName>Goetz</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au8" creatorRole="author" affiliationRef="#af12">
<personName>
<givenNames>Werner</givenNames>
<familyName>Poewe</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au9" creatorRole="author" affiliationRef="#af13">
<personName>
<givenNames>Olivier</givenNames>
<familyName>Rascol</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au10" creatorRole="author" affiliationRef="#af14">
<personName>
<givenNames>Cristina</givenNames>
<familyName>Sampaio</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au11" creatorRole="author" affiliationRef="#af11">
<personName>
<givenNames>Glenn</givenNames>
<familyName>Stebbins</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au12" creatorRole="author" affiliationRef="#af15">
<personName>
<givenNames>Anette</givenNames>
<familyName>Schrag</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="af1" countryCode="US" type="organization">
<unparsedAffiliation>NeuroHealth, Parkinson's Disease and Movement Disorders Center, Warwick, Rhode Island, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="US" type="organization">
<unparsedAffiliation>Department of Neurology, Warren Alpert Medical School, Brown University, Rhode Island, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="NO" type="organization">
<unparsedAffiliation>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="NO" type="organization">
<unparsedAffiliation>Department of Neurology, Stavanger University Hospital, Stavanger, Norway</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="SE" type="organization">
<unparsedAffiliation>Department of Neurology, Lund University Hospital, Lund, Sweden</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af6" countryCode="NL" type="organization">
<unparsedAffiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af7" countryCode="US" type="organization">
<unparsedAffiliation>Department of Psychiatry Johns Hopkins Hospital, Baltimore, Maryland, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af8" countryCode="US" type="organization">
<unparsedAffiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af9" countryCode="US" type="organization">
<unparsedAffiliation>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af10" countryCode="ES" type="organization">
<unparsedAffiliation>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af11" countryCode="US" type="organization">
<unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af12" countryCode="AT" type="organization">
<unparsedAffiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af13" countryCode="FR" type="organization">
<unparsedAffiliation>Clinical Investigation Center INSERM CIC‐9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af14" countryCode="PT" type="organization">
<unparsedAffiliation>Laboratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af15" countryCode="GB" type="organization">
<unparsedAffiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, United Kingdom</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author">
<keyword xml:id="kwd1">fatigue</keyword>
<keyword xml:id="kwd2">Parkinson's disease</keyword>
<keyword xml:id="kwd3">rating scales</keyword>
<keyword xml:id="kwd4">fatigue rating scales</keyword>
</keywordGroup>
<supportingInformation>
<p> Additional Supporting Information may be found in the online version of this article. </p>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22989:MDS_22989_sm_SuppMaterials1"></mediaResource>
<caption>Supporting Information Materials‐1.</caption>
</supportingInfoItem>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22989:MDS_22989_sm_SuppMaterials2"></mediaResource>
<caption>Supporting Information Materials‐2.</caption>
</supportingInfoItem>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22989:MDS_22989_sm_SuppMaterials3"></mediaResource>
<caption>Supporting Information Materials‐3.</caption>
</supportingInfoItem>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22989:MDS_22989_sm_SuppMaterials4"></mediaResource>
<caption>Supporting Information Materials‐4.</caption>
</supportingInfoItem>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22989:MDS_22989_sm_SuppMaterials5"></mediaResource>
<caption>Supporting Information Materials‐5.</caption>
</supportingInfoItem>
<supportingInfoItem>
<mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22989:MDS_22989_sm_SuppMaterials6"></mediaResource>
<caption>Supporting Information Materials‐6.</caption>
</supportingInfoItem>
</supportingInformation>
<abstractGroup>
<abstract type="main" xml:lang="en">
<title type="main">Abstract</title>
<p>Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was “recommended” if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of “recommended” differs from the use of this term in previous MDS task force scale reviews. “Suggested” scales failed to meet all the criteria of a “recommended” scale, usually the criterion of sensitivity to change in a study of PD. Scales were “listed” if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was “recommended” for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is “suggested” for both screening and severity. The Functional Assessment of Chronic Illness Therapy‐Fatigue was “recommended” for screening and “suggested” for severity. The Multidimensional Fatigue Inventory was “suggested” for screening and “recommended” for severity. The Parkinson Fatigue Scale was “recommended” for screening and “suggested” for severity rating. The Fatigue Severity Inventory was “listed” for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was “listed” for screening and “suggested” for severity. Visual Analogue and Global Impression Scales are both “listed” for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. © 2010 Movement Disorder Society</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup>
<note xml:id="fn1">
<p>Potential conflict of interest: None.</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en">
<title>Fatigue Rating Scales for Parkinson's Disease</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease</title>
</titleInfo>
<name type="personal">
<namePart type="given">Joseph H.</namePart>
<namePart type="family">Friedman</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>NeuroHealth, Parkinson's Disease and Movement Disorders Center, Warwick, Rhode Island, USA</affiliation>
<affiliation>Department of Neurology, Warren Alpert Medical School, Brown University, Rhode Island, USA</affiliation>
<description>Correspondence: NeuroHealth, 227 Centerville Rd, Warwick, RI 02886</description>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Guido</namePart>
<namePart type="family">Alves</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</affiliation>
<affiliation>Department of Neurology, Stavanger University Hospital, Stavanger, Norway</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Peter</namePart>
<namePart type="family">Hagell</namePart>
<namePart type="termsOfAddress">RN, PhD</namePart>
<affiliation>Department of Neurology, Lund University Hospital, Lund, Sweden</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Johan</namePart>
<namePart type="family">Marinus</namePart>
<namePart type="termsOfAddress">PhD</namePart>
<affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Laura</namePart>
<namePart type="family">Marsh</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Psychiatry Johns Hopkins Hospital, Baltimore, Maryland, USA</affiliation>
<affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA</affiliation>
<affiliation>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Pablo</namePart>
<namePart type="family">Martinez‐Martin</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Christopher G.</namePart>
<namePart type="family">Goetz</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Werner</namePart>
<namePart type="family">Poewe</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Olivier</namePart>
<namePart type="family">Rascol</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Clinical Investigation Center INSERM CIC‐9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Cristina</namePart>
<namePart type="family">Sampaio</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Laboratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Glenn</namePart>
<namePart type="family">Stebbins</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Anette</namePart>
<namePart type="family">Schrag</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, United Kingdom</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="reviewArticle"></genre>
<originInfo>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place>
<placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2010-05-15</dateIssued>
<dateCaptured encoding="w3cdtf">2009-07-20</dateCaptured>
<dateValid encoding="w3cdtf">2009-12-11</dateValid>
<copyrightDate encoding="w3cdtf">2010</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
<extent unit="tables">1</extent>
<extent unit="references">142</extent>
<extent unit="words">13773</extent>
</physicalDescription>
<abstract lang="en">Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was “recommended” if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of “recommended” differs from the use of this term in previous MDS task force scale reviews. “Suggested” scales failed to meet all the criteria of a “recommended” scale, usually the criterion of sensitivity to change in a study of PD. Scales were “listed” if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was “recommended” for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is “suggested” for both screening and severity. The Functional Assessment of Chronic Illness Therapy‐Fatigue was “recommended” for screening and “suggested” for severity. The Multidimensional Fatigue Inventory was “suggested” for screening and “recommended” for severity. The Parkinson Fatigue Scale was “recommended” for screening and “suggested” for severity rating. The Fatigue Severity Inventory was “listed” for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was “listed” for screening and “suggested” for severity. Visual Analogue and Global Impression Scales are both “listed” for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. © 2010 Movement Disorder Society</abstract>
<note type="content">*Potential conflict of interest: None.</note>
<subject lang="en">
<genre>Keywords</genre>
<topic>fatigue</topic>
<topic>Parkinson's disease</topic>
<topic>rating scales</topic>
<topic>fatigue rating scales</topic>
</subject>
<relatedItem type="host">
<titleInfo>
<title>Movement Disorders</title>
</titleInfo>
<titleInfo type="abbreviated">
<title>Mov. Disord.</title>
</titleInfo>
<genre type="Journal">journal</genre>
<note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information Materials‐1. - Supporting Information Materials‐2. - Supporting Information Materials‐3. - Supporting Information Materials‐4. - Supporting Information Materials‐5. - Supporting Information Materials‐6. - </note>
<subject>
<genre>article category</genre>
<topic>Review</topic>
</subject>
<identifier type="ISSN">0885-3185</identifier>
<identifier type="eISSN">1531-8257</identifier>
<identifier type="DOI">10.1002/(ISSN)1531-8257</identifier>
<identifier type="PublisherID">MDS</identifier>
<part>
<date>2010</date>
<detail type="volume">
<caption>vol.</caption>
<number>25</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>7</number>
</detail>
<extent unit="pages">
<start>805</start>
<end>822</end>
<total>18</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">076625E4756FDC12B6C3DF53275FFFA0F813F43F</identifier>
<identifier type="DOI">10.1002/mds.22989</identifier>
<identifier type="ArticleID">MDS22989</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition>
<recordInfo>
<recordContentSource>WILEY</recordContentSource>
<recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E88 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E88 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:076625E4756FDC12B6C3DF53275FFFA0F813F43F
   |texte=   Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024